Will Argentina be a Leading Exporter of Lithium?

Argentina is currently the world's third-largest lithium producer. Is it on its way to becoming the world's largest exporter of the metal?

The post Will Argentina be a Leading Exporter of Lithium? appeared first on Investing News Network.


John Kaiser: The Zinc Price Will Go a Lot Higher Than People Expect

Kaiser mentions two companies that he thinks could do well if the zinc price continues to rise.

The post John Kaiser: The Zinc Price Will Go a Lot Higher Than People Expect appeared first on Investing News Network.


Top Gold Producing Countries

Here's a look at the world's top gold producing countries, as per the most recent data from the United States Geological Survey.

The post Top Gold Producing Countries appeared first on Investing News Network.


10 Top Zinc-producing Countries

Curious about top zinc production in world by country? According to the US Geological Survey, China remained the top producer in 2016 by a long shot.

The post 10 Top Zinc-producing Countries appeared first on Investing News Network.


2016 TSX Venture 50: Best Technology Stocks to Invest In

Investors looking for the best technology stocks to invest in should consult the TSX Venture 50 list. Here's an overview of the tech companies on this year's list.

The post 2016 TSX Venture 50: Best Technology Stocks to Invest In appeared first on Investing News Network.


Falco Commences 40,000 Metre Drill Program

Falco Resources Ltd. (TSX.V: FPC) is pleased to announce that it is initiating exploration activities on its large 668 square kilometre land package in the Rouyn-Noranda Camp, which surrounds it’s 100% owned Horne 5 Project. The planned 40,000 metre exploration drill campaign is part of a $10 million budget allocated to 2017 exploration work. The exploration program will concentrate on eight different areas, including the Horne 5 project, with the objective of discovering new mineralization in the prolific past-producing Rouyn-Noranda camp.

The post Falco Commences 40,000 Metre Drill Program appeared first on Investing News Network.


Tabula Rasa HealthCare moves its San Francisco-based Operations

Tabula Rasa HealthCare (NASDAQ:TRHC), a healthcare technology company providing medication safety solutions for health plans and provider groups, including the Centers for Medicare and Medicaid Services’ (CMS) Program for All-Inclusive Care of the Elderly (PACE), has relocated its California medication decision support and robotic dispensary.
According to TRHC Chairman and CEO Calvin H. Knowlton, PhD, “We were

The post Tabula Rasa HealthCare moves its San Francisco-based Operations appeared first on Investing News Network.


NewLink Genetics to Host Its Fourth Quarter and Year End 2016 Financial Results Conference Call on February 28, 2017

NewLink Genetics Corporation (NASDAQ:NLNK), today reported that it will release its fourth quarter and year end 2016 financial results on Tuesday, February 28, 2017.  The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results and to give an update on clinical and business development activities.
NewLink Genetics’ senior

The post NewLink Genetics to Host Its Fourth Quarter and Year End 2016 Financial Results Conference Call on February 28, 2017 appeared first on Investing News Network.


athenahealth Partners with Specialty Medical Societies to Roll Out Network Medicine Health Campaigns

athenahealth, Inc. (NASDAQ:ATHN), a leading provider of network-enabled services and mobile applications for healthcare providers nationwide, today announced that it will roll out a series of “Network Medicine” health campaigns. Working in collaboration with preeminent specialty societies, including the American Association of Orthopedic Surgeons (AAOS), the American College of Cardiology (ACC), and The American College

The post athenahealth Partners with Specialty Medical Societies to Roll Out Network Medicine Health Campaigns appeared first on Investing News Network.


Immuron Completes Phase II NASH Clinical Trial Recruitment

Immuron Limited (ASX:IMC), an Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products to target immune-mediated diseases, today announced that the Company’s IMM-124E Phase II clinical trial for the treatment of NASH (Non-Alcoholic Steatohepatitis) has successfully reached its full recruitment milestone of 120 randomized patients.
The Phase II, multicenter, double blind randomized clinical study

The post Immuron Completes Phase II NASH Clinical Trial Recruitment appeared first on Investing News Network.